Cocrystal Pharma, Inc. (COCP) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Cocrystal Pharma Inc (COCP) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Cocrystal Pharma is a tiny clinical-stage biotech betting on antiviral drug development, and right now the stock is trading more on pipeline progress—especially CDI-988—than on any existing business fundamentals. > **📍 Basic Profile** > > Market Cap **$20.8 million** · Pharmaceuticals · NASDAQ NMS - GLOBAL MARKET · Price **$1.51** > **⚡ 3 Things You Should Know** > > 1. 📈 **Pipeline-Driven Pop:** The stock just surged after the FDA granted Fast Track status to CDI-988. That matters because for a company this small, regulatory validation can dramatically improve investor sentiment and strategic optionality—but it also means the share price can swing hard on each trial update. > > 2. ⚠️ **No Real Profit Engine Yet:** COCP has a gross margin on paper, but the bottom line is deeply negative, with net margin at **-480.1%** and ROE at **-129.69%**. In other words, this is not a “business compounding earnings”—it’s still a development-stage story consuming capital while investors wait for drug candidates to prove themselves. > > 3. 💰 **Balance Sheet Better Than Most Micro Biotechs:** What’s interesting is that COCP appears to have **no meaningful debt** and very strong liquidity, with a current ratio of **5.78**. So the near-term financial stress looks lower than many peers, but cash burn still matters because without commercial revenue, future dilution is always on the table. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -480.1%, deeply loss-making | > | Growth Rate | [Data unavailable] | Revenue growth data not provided; story is pipeline-driven | > | Financial Health | Healthy💚 | Debt ratio ~0%, current ratio 5.78 | > | Valuation | Pricey | PS 10.36x, no meaningful PE due to losses | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Antiviral drug candidates developed for future licensing, partnership, or commercialization, with current economics still mainly tied to R&D-stage progress rather than recurring product sales. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Antiviral drug development / collaboration-related revenue | [Data unavailable] | [Data unavailable] | COCP is still primarily a clinical-stage biotech rather than a diversified operating company | | Commercial product revenue | [Data unavailable] | [Data unavailable] | No evidence here of a meaningful established product revenue base | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 41.18% | Average | Suggests some reported revenue exists, but not enough to cover operating costs | | Net Margin | -480.1% | Below Average | Basically means losses massively exceed revenue | | ROE | -129.69% | Average | Equity is being consumed by ongoing losses; typical of early-stage biotech but still a red flag | --- #### 📈 How's the Growth? **Growth Assessment:** [Data unavailable] / Pipeline Momentum Improving | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | Quarterly losses improved | [Data unavailable] | Improving on EPS basis | **Growth Quality:** > Worth noting: COCP’s “growth” should not be read like a normal company’s sales growth story. What you might care about is clinical and regulatory progress. Recent signals are encouraging—Fast Track designation for CDI-988 and upcoming/ongoing Phase 1b data presentations—but this is still pre-commercial progress, not proven market adoption. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup scientist with cash in the bank and almost no debt, but no stable paycheck yet. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt-to-equity annual | <60% safe | ✅Safe | | Current Ratio | 5.78 | >1.5 healthy | ✅Safe | | Cash Flow | Cash flow/share TTM -1.95 | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.8588 - 52-Week High: $2.67 - Current: $1.51, **in the middle**, but closer to the lower half of the range after a sharp recent spike | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | ●(36% position) | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PS 10.36x | Industry avg [Data unavailable] | Hard to justify on revenue alone for a loss-making micro biotech | **What the Current Valuation is Betting On:** > Basically, the market is betting CDI-988 and the broader antiviral pipeline can create meaningful future value—through successful trials, partnerships, or eventual commercialization. Since there’s no earnings base to anchor valuation, investor expectations can re-rate quickly both up and down. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-01 | FDA grants Fast Track designation to CDI-988 | **Positive** — This is the clearest recent catalyst and helps validate the program’s importance | | 2026-03-30 | Q4 EPS of **$(0.17)** beat estimate | **Positive** — Still loss-making, but burn came in better than expected | | 2026-02-19 | CDI-988 data to be presented at ICAR 2026 | **Neutral to Positive** — Conference visibility helps, but investors still need strong clinical data, not just presentations | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 41.18% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -480.1% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -129.69% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | Losses narrowing on recent EPS | [Data unavailable] | [Data unavailable] | Improving recently | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $(0.18) | $(0.17) | +4.76% Beat 😀 | | 2025-09-30 | $(0.21) | $(0.19) | +11.30% Beat 😀 | | 2025-06-30 | $(0.31) | $(0.20) | +34.64% Beat 😀 | | 2025-03-31 | $(0.52) | $(0.23) | +55.35% Beat 😀 | **Earnings Trend Interpretation:** COCP has beaten estimates for four straight quarters, which is a good sign on cost control versus expectations. That said, these are still losses, so the takeaway isn’t “the business is profitable”—it’s more that management is burning less cash than analysts feared. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 7 firms | 87.5% | | Hold | 1 firm | 12.5% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net **buying** in past 3 months > What’s interesting is that Phillip Frost reported open-market purchases of **20,000 shares** on 2026-02-24 and **50,000 shares** on 2026-02-06. That usually reads as a favorable signal, especially for a micro-cap biotech. Some of the other January filings look like stock awards rather than conviction buys, so I’d put more weight on the open-market purchases. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Clinical Trial Risk:** COCP’s valuation depends heavily on CDI-988 and other antiviral programs → If trial data disappoints, the stock could rerate sharply lower 2. **Financing/Dilution Risk:** The company has negative cash flow and no established profit base → If development timelines stretch, it may need to issue more shares 3. **Commercialization Risk:** Even if the science works, biotech value creation still requires successful regulatory execution, partnerships, or market adoption → If those steps stall, shareholder returns may lag despite positive early data --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** COCP is a micro-cap clinical-stage antiviral biotech, so this is mainly a pipeline bet rather than a fundamentals-and-cash-flow story. > > **Key strength:** The balance sheet looks cleaner than many tiny biotechs, and recent catalysts—especially FDA Fast Track status plus consistent EPS beats—have improved sentiment. > > **Key risk:** The business is still deeply unprofitable, so if clinical progress slows or capital needs rise, dilution and volatility can hit hard. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis